Affiliate disclosure: Digital Adsvertic is an independent publisher. We may receive compensation if you use an affiliate link on this page. Check the advertiser’s current terms before taking action.
NEXLIZET is a prescription cholesterol medicine that combines bempedoic acid 180 mg and ezetimibe 10 mg in one tablet. It is used along with diet and exercise to lower low-density lipoprotein cholesterol, commonly called LDL-C or “bad” cholesterol, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
This guide explains what the medicine offers, how it differs from NEXLETOL, what the clinical evidence shows, and which safety and access questions matter. NEXLIZET is not appropriate for everyone, and only a healthcare professional who knows your medical history can determine whether it belongs in your treatment plan.
NEXLIZET for Adults Who Need Additional LDL-C Lowering
NEXLIZET gives prescribers a nonstatin option containing two active ingredients with different actions. Bempedoic acid reduces cholesterol synthesis in the liver, while ezetimibe reduces the absorption of cholesterol in the small intestine. The combination is taken as one tablet once daily.
What NEXLIZET actually offers
The medicine’s labeled purpose is to help lower LDL-C when used with diet and exercise. It is not a substitute for either of those measures, and the label does not promise that every patient will reach a particular cholesterol number. Individual results can depend on baseline LDL-C, other medicines, medical history and adherence.
Key features of the prescription include:
- Two medicines in one tablet: Each dose contains bempedoic acid and ezetimibe.
- Once-daily administration: The tablet may be taken with or without food.
- Nonstatin ingredients: Neither active ingredient is a statin, although NEXLIZET may be used in treatment plans that include an allowed statin dose.
- Laboratory follow-up: The FDA label recommends checking lipid levels within eight to 12 weeks after treatment begins.
The complete indication, administration instructions and safety information are available in the current FDA prescribing information.
NEXLIZET and NEXLETOL are not the same product
The similar names can cause confusion. NEXLETOL contains bempedoic acid alone. NEXLIZET contains the same dose of bempedoic acid plus ezetimibe. They are separate prescriptions and should not be treated as interchangeable names.
This distinction also matters when reading research. A study of bempedoic acid alone does not automatically establish the same finding for the fixed-dose NEXLIZET tablet. Patients should verify the brand, active ingredients and tablet instructions on their prescription rather than relying on a shortened product name.
Who may be considered for treatment?
NEXLIZET is labeled for adults with hypercholesterolemia, including adults with heterozygous familial hypercholesterolemia. A prescriber may consider numerous factors before recommending it, such as a patient’s current LDL-C, cardiovascular risk, response to existing therapy, side effects from previous medicines and potential drug interactions.
Useful questions for a medical appointment include:
- What is my current LDL-C, and what treatment goal are we working toward?
- Why are you considering the combination instead of either ingredient alone?
- Should I continue my current cholesterol medicines?
- Do my history of gout, tendon problems, liver disease or medication reactions affect suitability?
- When will my cholesterol and other relevant laboratory results be checked?
NEXLIZET is not a general wellness supplement or an over-the-counter cholesterol remedy. It requires a prescription and individualized clinical review.
What the LDL-C study found
In the combination-product trial summarized in FDA labeling, adults with hypercholesterolemia received NEXLIZET, bempedoic acid, ezetimibe or placebo while taking maximally tolerated statin therapy. At 12 weeks, the placebo-corrected difference in mean LDL-C change for NEXLIZET was minus 38 percentage points.
That result supports the medicine’s LDL-lowering indication, but context is important. It came from a relatively short trial focused on a lipid endpoint. It should not be presented as a guarantee of an individual response or as independent proof that the fixed combination prevents every possible cardiovascular event. Follow-up testing is how a patient and prescriber assess the actual response.
How the cardiovascular evidence should be understood
Bempedoic acid, one component of NEXLIZET, also has labeled cardiovascular-risk-reduction language for adults at increased risk who cannot take recommended statin therapy, including patients taking no statin. The component-level wording should be preserved rather than converted into an unrestricted claim about the combination tablet.
In CLEAR Outcomes, participants had cardiovascular disease or were at elevated risk and were unable or unwilling to take statins because of adverse effects. A primary composite cardiovascular event occurred in 11.7% of the bempedoic acid group and 13.3% of the placebo group, with a hazard ratio of 0.87. The published CLEAR Outcomes study evaluated bempedoic acid, not NEXLIZET as a fixed combination.
These findings may be relevant to a clinician’s broader treatment decision, but they do not mean that NEXLIZET eliminates cardiovascular risk. Cholesterol management often remains one part of a plan addressing blood pressure, diabetes, tobacco exposure, physical activity, nutrition and other risk factors.
Potential practical benefits
For an appropriately selected adult, NEXLIZET’s main practical feature is the inclusion of two LDL-lowering medicines in one daily tablet. That may simplify the number of separate cholesterol tablets in a regimen, although it does not necessarily reduce the total number of medications a person takes.
Potential benefits to discuss with a prescriber include:
- Additional LDL-C lowering through two different mechanisms.
- A nonstatin combination for patients whose treatment plan calls for both ingredients.
- One fixed dose instead of separate bempedoic acid and ezetimibe tablets.
- Administration without a food requirement.
A fixed-dose combination also provides less flexibility to adjust the two ingredients independently. If a patient needs only one component, cannot tolerate one ingredient or requires a different strategy, another prescription may be more appropriate.
How to Get Started With NEXLIZET
Starting NEXLIZET involves more than requesting a specific brand. A healthcare professional must confirm the indication, review relevant risks and decide how the medicine would fit with current therapy. Coverage and out-of-pocket costs should also be checked before the prescription is filled.
Have a focused healthcare visit
Bring an up-to-date medication list, recent cholesterol results if available, and details about previous cholesterol treatments. Tell the clinician why a medicine was stopped, including the symptom, timing and whether it improved afterward. “I could not take it” is less informative than a clear description of what occurred.
Also disclose gout or elevated uric acid, tendon disorders or injuries, kidney problems, liver problems, pregnancy plans and past allergic reactions. These details can affect risk assessment, monitoring or the choice of another medicine.
Confirm the full medication list
The review should include prescriptions, over-the-counter products, vitamins and supplements. It is particularly important to identify statins and bile-acid sequestrants. The label says to avoid using NEXLIZET with simvastatin doses above 20 mg or pravastatin doses above 40 mg because bempedoic acid increases concentrations of those statins and may increase muscle-related risk.
If NEXLIZET is used with a bile-acid sequestrant, take it at least two hours before or at least four hours after that medicine. Patients should ask a pharmacist to map out the schedule if the instructions are difficult to coordinate.
Take the tablet correctly
The labeled dose is one tablet by mouth once daily, with or without food. Swallow it whole. Do not change the dose, split the tablet or stop other cholesterol medicines unless the prescriber gives specific instructions.
Practical habits can support consistent use:
- Choose a regular time that works with any spacing requirements.
- Use a pill organizer only after confirming the tablet can be stored that way.
- Ask the pharmacist what to do about a missed dose rather than doubling doses.
- Keep the medicine in its labeled container and follow the storage instructions.
- Refill early enough to avoid an unintended treatment gap.
The official NEXLIZET consumer website provides current brand information, but personalized dosing and medication questions belong with the prescriber or pharmacist.
Complete follow-up testing
The prescribing information recommends analyzing lipid levels within eight to 12 weeks after starting NEXLIZET. A clinician may arrange other monitoring based on symptoms, medical history and concomitant medicines. Patients should keep follow-up appointments even when they feel no different, because high LDL-C generally cannot be assessed by symptoms.
At follow-up, ask how much LDL-C changed, whether the response is adequate and whether the complete regimen should continue. Do not assume that an improved result means diet, exercise or other prescribed therapies are no longer necessary.
Important Safety Information and Eligibility Considerations
NEXLIZET has meaningful risks as well as potential benefits. The most prominent labeled warnings involve elevated uric acid and tendon rupture. A balanced decision should account for those risks before treatment and for new symptoms after it begins.
Hyperuricemia and gout
Bempedoic acid can raise blood uric acid levels and may cause gout. Increases may occur early and persist during treatment. Tell the prescriber about previous gout attacks or elevated uric acid before starting the medicine.
Contact a healthcare professional if symptoms suggestive of gout develop, such as sudden severe joint pain, redness, warmth or swelling. The clinician may check uric acid when clinically indicated and decide whether treatment for elevated uric acid or a change in cholesterol therapy is needed.
Tendon injury and rupture
Bempedoic acid is associated with an increased risk of tendon rupture or injury. Events may involve the rotator cuff, biceps tendon or Achilles tendon and can occur within weeks or months of starting treatment. Risk may be greater in people older than 60, those taking corticosteroids or fluoroquinolone antibiotics, people with renal failure and those with previous tendon disorders.
Stop the medicine and obtain medical advice promptly at the first sign of tendon rupture. The label also advises considering discontinuation if joint pain, swelling or inflammation develops. Avoid strenuous use of an affected area until it has been medically evaluated.
Allergic reactions and other side effects
NEXLIZET is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid, ezetimibe or the product’s other ingredients. Report swelling, hives, breathing difficulty or other possible allergic symptoms immediately and seek emergency care when symptoms are severe.
Adverse reactions reported in the labeled clinical programs include hyperuricemia, muscle spasms, elevated liver enzymes, anemia, diarrhea, pain in an extremity and other conditions. This is not a complete side-effect list. Patients can review the medication information and ask which symptoms require urgent care versus a routine call.
Pregnancy, breastfeeding and liver impairment
The label warns that NEXLIZET may cause fetal harm based on how it works. It generally should be discontinued when pregnancy is recognized unless the clinician determines that continued treatment offers a benefit that justifies the potential risk. Patients who are pregnant, may become pregnant or are breastfeeding should discuss the current label guidance with their clinician.
NEXLIZET is not recommended for patients with moderate or severe hepatic impairment because of the unknown effects of increased ezetimibe exposure. A history of liver disease or abnormal liver tests should be raised before treatment begins.
Prescription, coverage and program terms
Medical eligibility does not guarantee insurance coverage. Formularies may require prior authorization, documentation of previous therapies or use of another covered drug first. The prescriber’s office and dispensing pharmacy can help identify the plan’s current requirements.
Before filling the prescription, patients can ask:
- Is NEXLIZET covered by my specific plan and pharmacy network?
- Does the insurer require prior authorization or step therapy?
- What will my out-of-pocket amount be for this fill?
- Would a manufacturer support program apply to my insurance type?
- Are there restrictions, expiration dates or renewal steps?
Manufacturer assistance and savings-program rules can change and commonly depend on insurance status and other conditions. Read the current terms rather than assuming that advertised support applies. Medicare, Medicaid and other government-insured patients may face different restrictions from commercially insured patients. Never delay necessary care while waiting for a discount determination without contacting the prescriber.
Frequently Asked Questions About NEXLIZET
Is NEXLIZET a statin?
No. NEXLIZET contains bempedoic acid and ezetimibe, neither of which is a statin. However, being nonstatin does not make the medicine risk-free or automatically suitable for everyone who has experienced statin side effects. It may be prescribed with certain statin regimens, subject to interaction-related dose limits.
Does NEXLIZET replace diet and exercise?
No. Its approved use is as an adjunct to diet and exercise. Patients should continue the nutrition, activity and risk-reduction plan recommended by their healthcare professional. Anyone with physical limitations or cardiovascular disease should seek individualized advice before making a major exercise change.
How quickly will NEXLIZET lower cholesterol?
The label recommends checking lipids within eight to 12 weeks after initiation. That testing window gives the clinician an opportunity to measure response and reconsider the regimen. It is not a promise that every patient will achieve a specific result by a particular day.
Can NEXLIZET prevent a heart attack or stroke?
The labeling states that bempedoic acid, one component of NEXLIZET, reduces the risk of major adverse cardiovascular events in certain adults at increased risk who cannot take recommended statin therapy. The pivotal cardiovascular outcomes trial studied bempedoic acid rather than the fixed-dose combination itself. A clinician can explain how that evidence applies to an individual’s risk profile.
Can NEXLIZET be taken with food?
Yes. The tablet may be taken with or without food and should be swallowed whole once daily. Timing changes are necessary when it is used with a bile-acid sequestrant: NEXLIZET should be taken at least two hours before or four hours after that medicine.
What if I already take ezetimibe or NEXLETOL?
Tell the prescriber before starting NEXLIZET. Because NEXLIZET already contains both ezetimibe and bempedoic acid, taking separate products could unintentionally duplicate an ingredient. Do not combine, substitute or discontinue these prescriptions without explicit instructions.
Who should not take NEXLIZET?
People with a prior serious hypersensitivity reaction to bempedoic acid, ezetimibe or any product ingredient should not take it. Other conditions may make treatment inadvisable or require extra consideration, including pregnancy, moderate or severe liver impairment, gout risk, tendon disorders and interacting medications. Final eligibility requires a clinician’s review.
What should I do if I develop pain while taking it?
New pain should not automatically be dismissed as ordinary soreness. Sudden tendon pain, swelling, bruising, weakness or difficulty moving an area warrants prompt medical advice, especially around the heel, shoulder or upper arm. Severe joint pain with redness and warmth may suggest gout. Follow the urgent-care instructions provided by a healthcare professional.
Is NEXLIZET guaranteed to be covered by insurance?
No. Coverage varies by insurer, plan, pharmacy network and current formulary rules. Ask the pharmacy for a real-time price and ask the insurer whether authorization is required. If coverage is denied, the prescriber can determine whether an appeal, supporting documentation or a different treatment is appropriate.
Where can I find the most current information?
Start with the current FDA-approved prescribing information and medication guide, then confirm personalized instructions with a healthcare professional. Labeling, coverage and support-program terms can change. Using current official materials helps prevent decisions based on an older indication, outdated safety language or expired financial-assistance terms.
Leave a Reply